Cargando…

Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.

Rhizoxin is a new anti-tumour agent isolated from the pathogenic fungus Rhizopus chinensis. It has shown broad activity against murine tumour models and is also active against vinca alkaloid-resistant cells. The purpose of our studies was to determine the clinical activity of this compound in patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hanauske, A. R., Catimel, G., Aamdal, S., ten Bokkel Huinink, W., Paridaens, R., Pavlidis, N., Kaye, S. B., te Velde, A., Wanders, J., Verweij, J.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1996
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074418/ https://www.ncbi.nlm.nih.gov/pubmed/8562349

Ejemplares similares

Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group.
por: Kaplan, S., et al.
Publicado: (1996)

Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.
por: McLeod, H. L., et al.
Publicado: (1996)

Phase II study of rhizoxin in squamous cell head and neck cancer. The EORTC Early Clinical Trials Group.
por: Verweij, J., et al.
Publicado: (1996)

Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study.
por: Sternberg, C. N., et al.
Publicado: (1994)

Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)
por: Cerny, T., et al.
Publicado: (1994)

Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer.
por: Kerr, D. J., et al.
Publicado: (1995)

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.
por: Sulkes, A., et al.
Publicado: (1994)

Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group.
por: de Wit, R., et al.
Publicado: (1995)

Ring-Closing Metathesis Approaches towards the Total Synthesis of Rhizoxins
por: Liniger, Marc, et al.
Publicado: (2020)

Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer.
por: de Wit, R., et al.
Publicado: (1998)

Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group.
por: Fosså, S. D., et al.
Publicado: (1995)

Inhibition of Angiogenesis by Rhizoxin, a Microbial Metabolite Containing Two Epoxide Groups
por: Onozawa, Chizuko, et al.
Publicado: (1997)

EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer
por: Van den Brande, J, et al.
Publicado: (2003)

Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer
por: Terwogt, J M M, et al.
Publicado: (1999)

Surgical management of melanoma: an EORTC Melanoma Group survey
por: Testori, A, et al.
Publicado: (2013)

International clinical trials setting for rare cancers: organisational and regulatory constraints—the EORTC perspective
por: Shash, Emad, et al.
Publicado: (2013)

Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials
por: Gamper, Eva M., et al.
Publicado: (2021)

Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 “CREATE” Trial
por: Lee, Che-Jui, et al.
Publicado: (2022)

Mitozolomide (NSC 353451), a new active drug in the treatment of malignant melanoma. Phase II trial in patients with advanced disease.
por: Gundersen, S., et al.
Publicado: (1987)

Sentinel Node Identification Rate and Nodal Involvement in the EORTC 10981-22023 AMAROS Trial
por: Straver, Marieke E., et al.
Publicado: (2010)

Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial.
por: Elferink, F., et al.
Publicado: (1987)

Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.
por: de Wit, R., et al.
Publicado: (1998)

Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
por: de Wit, R., et al.
Publicado: (1997)

Integration of Translational Research in the European Organization for Research and Treatment of Cancer Research (EORTC) Clinical Trial Cooperative Group Mechanisms
por: Lehmann, Frederic, et al.
Publicado: (2003)

Lungtech, a phase II EORTC trial of SBRT for centrally located lung tumours – a clinical physics perspective
por: Lambrecht, Marie, et al.
Publicado: (2016)

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
por: Hamid, Omid, et al.
Publicado: (2011)

Melanoma risk and residence in sunny areas. EORTC Melanoma Co-operative Group. European Organization for Research and Treatment of Cancer.
por: Autier, P., et al.
Publicado: (1997)

Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial
por: Michels, Judith, et al.
Publicado: (2018)

The Clinical Trial Landscape for Melanoma Therapies
por: Wróbel, Sonia, et al.
Publicado: (2019)

Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.
por: Dercksen, M. W., et al.
Publicado: (1993)

Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23
por: Hau, Peter, et al.
Publicado: (2021)

Effects of patient selection on the applicability of results from a randomised clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS
por: Bijker, N, et al.
Publicado: (2002)

Challenges Conveying Clinical Equipoise and Exploring Patient Treatment Preferences in an Oncology Trial Comparing Active Monitoring with Radiotherapy (ROAM/EORTC 1308)
por: Sherratt, Frances C., et al.
Publicado: (2020)

Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial
por: Kawahara, Takuya, et al.
Publicado: (2022)

Comprehensive Survey of Clinical Trials Registration for Melanoma Immunotherapy in the ClinicalTrials.gov
por: Wang, Yan-Bo, et al.
Publicado: (2020)

Assessing quality of life in a randomized clinical trial: Correcting for missing data
por: Gunnes, Nina, et al.
Publicado: (2009)

Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion
por: Vinholes, J, et al.
Publicado: (1999)

Impact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trials
por: van der Hage, Jos A, et al.
Publicado: (2011)

Organ Preservation and Late Functional Outcome in Oropharyngeal Carcinoma: Rationale of EORTC 1420, the “Best of” Trial
por: Stelmes, Jean-Jacques, et al.
Publicado: (2019)

Translation and validation of the EORTC brain cancer module (EORTC QLQ-BN20) for use in Iran
por: Khoshnevisan, Alireza, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_lvodm6gesofkej4mmg9fkv4q31